Drugs / AZD4041
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06406400 | May → Jul 2024 | opiate dependence | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT05587998 | Aug 2022 → May 2023 | substance-related disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05233085 | Dec 2021 → Jun 2022 | opiate dependence | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04076540 | Oct 2019 → Jan 2022 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05233085 ↗ |
| Route | Oral | “Administration by Oral syringe” NCT04076540 ↗ |